Submitted:
03 June 2025
Posted:
05 June 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Results and Discussion
2.1. Energy Values and Conversions
2.2. Target Validation
2.3. Virtual Screening Analysis
2.4. ROC Curves and Enrichment Factors Analysis
3. Materials and Methods
3.1. Protein Preparation
3.2. Dataset and 3D Structures Generation
3.3. Molecular Docking Analysis
3.4. RMSD Calculation
3.5. Decoys Generation
3.6. ROC Curves and Enrichment Factors
4. Conclusions
Supplementary Materials
Funding
Data Availability Statement
Conflicts of Interest
Abbreviations
| %SR | Success Rate Percentage |
| AI | Artificial Intelligence |
| ALPB | Analytical Linearized Poisson-Boltzmann |
| AUC | Area Under Curve |
| CNNs | Convolutional Neural Networks |
| EF | Enrichment Factor |
| FPF | False Positive Fraction |
| FPR | False Positive Rate |
| GPUs | Graphics Processing Units |
| MCMC | Markov Chain Monte Carlo |
| MD | Molecular Dynamics |
| RMSD | Root Mean Square Deviation |
| ROC | Receiver Operating Characteristic Curve |
| TPF | True Positive Fraction |
| TPR | True Positive Rate |
| VS | Virtual Screening |
References
- Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935–949. [Google Scholar] [CrossRef] [PubMed]
- Pinzi, L.; Rastelli, G. Molecular Docking: Shifting Paradigms in Drug Discovery. IJMS 2019, 20, 4331. [Google Scholar] [CrossRef] [PubMed]
- Fischer, A.; Smieško, M.; Sellner, M.; Lill, M.A. Decision Making in Structure-Based Drug Discovery: Visual Inspection of Docking Results. J. Med. Chem. 2021, 64, 2489–2500. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, L.; Dos Santos, R.; Oliva, G.; Andricopulo, A. Molecular Docking and Structure-Based Drug Design Strategies. Molecules 2015, 20, 13384–13421. [Google Scholar] [CrossRef]
- De Ruyck, J.; Brysbaert, G.; Blossey, R.; Lensink, M. Molecular docking as a popular tool in drug design, an in silico travel. AABC 2016, Volume 9, 1–11. [Google Scholar] [CrossRef]
- Vieira, T.F.; Sousa, S.F. Comparing AutoDock and Vina in Ligand/Decoy Discrimination for Virtual Screening. App. Sci. 2019, 9, 4538. [Google Scholar] [CrossRef]
- Sunseri, J.; Koes, D.R. Virtual Screening with Gnina 1.0. Molecules 2021, 26, 7369. [Google Scholar] [CrossRef]
- Rentzsch, R.; Renard, B.Y. Docking small peptides remains a great challenge: an assessment using AutoDock Vina. Brief. Bioinform. 2015, 16, 1045–1056. [Google Scholar] [CrossRef]
- Chang, M.W.; Ayeni, C.; Breuer, S.; Torbett, B.E. Virtual Screening for HIV Protease Inhibitors: A Comparison of AutoDock 4 and Vina. PLoS ONE 2010, 5, e11955. [Google Scholar] [CrossRef]
- McNutt, A.T.; Francoeur, P.; Aggarwal, R.; Masuda, T.; Meli, R.; Ragoza, M.; Sunseri, J.; Koes, D.R. GNINA 1.0: molecular docking with deep learning. J. Cheminform. 2021, 13, 43. [Google Scholar] [CrossRef]
- McNutt, A.T.; Li, Y.; Meli, R.; Aggarwal, R.; Koes, D.R. GNINA 1.3: the next increment in molecular docking with deep learning. J. Cheminform. 2025, 17, 28. [Google Scholar] [CrossRef] [PubMed]
- Dunn, I.; Pirhadi, S.; Wang, Y.; Ravindran, S.; Concepcion, C.; Koes, D.R. CACHE Challenge #1: Docking with GNINA Is All You Need. J. Chem. Inf. Model. 2024, 64, 9388–9396. [Google Scholar] [CrossRef] [PubMed]
- Domínguez-Ramírez, L.; Anaya-Ruiz, M.; Cortés-Hernández, P. Quality over quantity: how to get the best results when using docking for repurposing. Front. Bioinform. 2025, 5, 1536504. [Google Scholar] [CrossRef]
- Ramírez, D.; Caballero, J. Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? Molecules 2018, 23, 1038. [Google Scholar] [CrossRef]
- Pereira, J.C.; Caffarena, E.R.; Dos Santos, C.N. Boosting Docking-Based Virtual Screening with Deep Learning. J. Chem. Inf. Model. 2016, 56, 2495–2506. [Google Scholar] [CrossRef]
- Empereur-mot, C.; Guillemain, H.; Latouche, A.; Zagury, J.-F.; Viallon, V.; Montes, M. Predictiveness curves in virtual screening. J. Cheminform. 2015, 7, 52. [Google Scholar] [CrossRef]
- Wang, S.; Jiang, J.-H.; Li, R.-Y.; Deng, P. Docking-based virtual screening of TβR1 inhibitors: evaluation of pose prediction and scoring functions. BMC Chemistry 2020, 14, 52. [Google Scholar] [CrossRef]
- Shamsara, J. Correlation between Virtual Screening Performance and Binding Site Descriptors of Protein Targets. Int. J. Med. Chem. 2018, 2018, 1–10. [Google Scholar] [CrossRef]
- Cross, J.B.; Thompson, D.C.; Rai, B.K.; Baber, J.C.; Fan, K.Y.; Hu, Y.; Humblet, C. Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy. J. Chem. Inf. Model. 2009, 49, 1455–1474. [Google Scholar] [CrossRef]
- Chen, H.; Lyne, P.D.; Giordanetto, F.; Lovell, T.; Li, J. On Evaluating Molecular-Docking Methods for Pose Prediction and Enrichment Factors. J. Chem. Inf. Model. 2006, 46, 401–415. [Google Scholar] [CrossRef]
- Sander, T.; Freyss, J.; Von Korff, M.; Rufener, C. DataWarrior: An Open-Source Program for Chemistry Aware Data Visualization and Analysis. J. Chem. Inf. Model. 2015, 55, 460–473. [Google Scholar] [CrossRef] [PubMed]
- O’Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An open chemical toolbox. J. Cheminform. 2011, 3, 33. [Google Scholar] [CrossRef] [PubMed]
- Bannwarth, C.; Caldeweyher, E.; Ehlert, S.; Hansen, A.; Pracht, P.; Seibert, J.; Spicher, S.; Grimme, S. Extended tight-binding quantum chemistry methods. WIREs Comput. Mol. Sci. 2021, 11, e1493. [Google Scholar] [CrossRef]
- Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef] [PubMed]
- Bell, E.W.; Zhang, Y. DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism. J. Cheminform. 2019, 11, 40. [Google Scholar] [CrossRef]
- Alberca, L.N.; Prada Gori, D.N.; Fallico, M.J.; Fassio, A.V.; Talevi, A.; Bellera, C.L. LIDEB’s Useful Decoys (LUDe): A freely available decoy-generation tool. Benchmarking and scope. AI Life Sci. 2025, 7, 100129. [Google Scholar] [CrossRef]
- Empereur-Mot, C.; Zagury, J.-F.; Montes, M. Screening Explorer–An Interactive Tool for the Analysis of Screening Results. J. Chem. Inf. Model. 2016, 56, 2281–2286. [Google Scholar] [CrossRef]


| Protein name | Source database | PDB ID | Domain | CNN score |
|---|---|---|---|---|
| Acetylcholinesterase | PDB-REDO | 6O4W | B | 0.92 |
| Tyrosine-protein kinase ABL2 | RCSB PDB | 2XYN | C | 0.99 |
| Carbonic anhydrase II | PDB-REDO | 4HT2 | A | 0.90 |
| SYK kinase | PDB-REDO | 3EMG | A | 0.99 |
| Beta-secretase 1 | PDB-REDO | 4DJW | B | 0.98 |
| Cyclin-dependent kinase 2 | RCSB PDB | 1KE9 | A | 0.97 |
| Adenosine A2a receptor | PDB-REDO | 5OLH | A | 0.96 |
| Dopamine D3 receptor | RCSB PDB | 7BVQ | B | 0.98 |
| HSP90α | PDB-REDO | 4O09 | A | 0.96 |
| HDAC 6 | PDB-REDO | 5EDU | B | 0.97 |
| Protein name | pKexp | GNINA pKpred | GNINA RMSD | Vina pKpred | Vina RMSD |
|---|---|---|---|---|---|
| Acetylcholinesterase | 8.54–7.42 | 7.29 | 1.71 | 7.61 | 1.19 |
| Tyrosine-protein kinase ABL2 | 7.52–7.38 | 8.47 | 0.79 | 5.99 | 6.54 |
| Carbonic anhydrase II | 6.82–6.54 | 7.73 | 1.37 | 4.57 | 6.78 |
| SYK kinase | 8.05 | 7.85 | 0.97 | 6.29 | 1.04 |
| Beta-secretase 1 | 6.96 | 6.83 | 0.44 | 5.95 | 7.31 |
| Cyclin-dependent kinase 2 | 6.68–5.75 | 6.52 | 1.80 | 6.52 | 1.96 |
| Adenosine A2a receptor | 9.10–8.89 | 7.60 | 0.29 | 6.04 | 8.33 |
| Dopamine D3 receptor | 10.00–9.80 | 7.56 | 1.69 | 4.74 | 6.23 |
| HSP90α | 7.70–7.59 | 7.75 | 1.05 | 8.19 | 0.95 |
| HDAC 6 | 9.89–6.30 | 70.00 | 1.80 | 4.79 | 7.30 |
| Protein name | Input molecules a |
Hits b (GNINA) | Actives c (GNINA) | SR% d GNINA | Hits b (Vina) | Actives c (Vina) | SR% d Vina |
|---|---|---|---|---|---|---|---|
| Acetylcholinesterase | 790 | 148 | 90 | 64% | 532 | 233 | 44% |
| Tyrosine-protein kinase ABL2 | 92 | 20 | 11 | 55% | 41 | 16 | 39% |
| Carbonic anhydrase II | 502 | 149 | 146 | 98% | 2 | 1 | 50% |
| SYK kinase | 80 | 41 | 34 | 83% | 13 | 11 | 85% |
| Beta-secretase 1 | 2345 | 660 | 574 | 87% | 150 | 122 | 81% |
| Cyclin-dependent kinase 2 | 1322 | 726 | 655 | 90% | 386 | 285 | 74% |
| Adenosine A2a receptor | 7001 | 1630 | 1426 | 88% | 2839 | 2129 | 75% |
| Dopamine D3 receptor | 150 | 37 | 36 | 97% | 39 | 38 | 97% |
| HSP90α | 637 | 190 | 125 | 63% | 299 | 181 | 61% |
| HDAC 6 | 225 | 36 | 34 | 94% | 21 | 18 | 86% |
| Protein name | GNINA EF1% a |
Vina EF1% a |
GNINA EF5% b |
Vina EF5% b |
GNINA EF10% c |
Vina EF10% c |
|---|---|---|---|---|---|---|
| Acetylcholinesterase | 5.52 | 5.52 | 1 | 6.02 | 5.52 | 4.01 |
| Tyrosine-protein kinase ABL2 | 15 | 5 | 10 | 3 | 6 | 2.5 |
| Carbonic anhydrase II | 20.75 | 0 | 14.53 | 0 | 8.1 | 0 |
| SYK kinase | 10 | 10 | 12 | 3 | 7 | 3 |
| Beta-secretase 1 | 12.53 | 0 | 7.31 | 0 | 4.57 | 0 |
| Cyclin-dependent kinase 2 | 20.5 | 10.25 | 12.3 | 4.1 | 8 | 3 |
| Adenosine A2a receptor | 5.08 | 0 | 3.04 | 2.03 | 2.54 | 1.01 |
| Dopamine D3 receptor | 15.34 | 10.22 | 6.13 | 3.07 | 3.58 | 3.58 |
| HSP90α | 0 | 0 | 4.01 | 0 | 5.51 | 0 |
| HDAC 6 | 20.15 | 0 | 17.13 | 10.07 | 9.07 | 6.04 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).